Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop fordry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

Health Care

Health Diagnostics

Therapeutics

Cambium Medical Technologies

Terence A. Walts

Tina W. McKeon

Clayton W. Coley

Neera Jagirdar

Michael Broughton

Dennis E. Hannigan

John D. Roback

Edmund K. Waller

The Medical Advisory Team at Cambium Medical Technologies is responsible for providing expert clinical guidance and medical insights to support the development and commercialization of the company's regenerative therapies. This includes collaborating on the clinical trials, ensuring compliance with regulatory standards, and offering insights on the therapeutic efficacy and safety of the investigational drug Elate Ocular for dry eye syndrome.

Medical Advisory Team

Leadership Team

Legal and Regulatory Affairs Team

��

Medical Advisory Team

About

Team members

Other teams at Cambium Medical Technologies

Leadership Team

Legal and Regulatory Affairs Team

��������

Medical Advisory Team

About

Team members

Other teams at Cambium Medical Technologies

Leadership Team

Legal and Regulatory Affairs Team

��